Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.42 |
| ▸ | KLK7 | P49862 | 2/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923066 | 0.85 | MEN1 (0.38) | AGTR2MEN1KMT2A | |
| SCHEMBL30854490 | 0.85 | MEN1 (0.38) | AGTR2MEN1KMT2A | |
| SCHEMBL21906706 | 0.84 | MEN1 (0.47) | PREPSIGMAR1TMEM97MEN1KMT2A | |
| SCHEMBL20681649 | 0.83 | AGTR2 (0.47) | AGTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2148636 | 0.81 | SMN1; SMN2 (0.49) | PREPSIGMAR1TMEM97MEN1KMT2A | |
| SCHEMBL6515997 | 0.81 | AGTR2 (0.56) | AGTR2KLK7KLK5NPC1RAB9A | |
| SCHEMBL15241314 | 0.81 | AGTR2 (0.56) | AGTR2KLK7KLK5NPC1RAB9A | |
| SCHEMBL6281354 | 0.81 | AGTR2 (0.56) | AGTR2KLK7KLK5NPC1RAB9A | |
| SCHEMBL29921 | 0.81 | AGTR2 (0.56) | AGTR2KLK7KLK5NPC1RAB9A | |
| SCHEMBL578446 | 0.81 | SMN1; SMN2 (0.54) | PREPSIGMAR1TMEM97MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-3896056-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020122182-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | 中外製薬株式会社 | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | PREP 33/4885AGTR2 2416/4885KLK7 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.